Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
Status: | Completed |
---|---|
Conditions: | Neurology |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/8/2018 |
Start Date: | September 13, 2010 |
End Date: | October 19, 2018 |
A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to collect long-term safety and tolerability, long-term
efficacy, and health outcome data in all patients currently ongoing in the fingolimod
multiple sclerosis clinical development program. This study will combine all currently
ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned
studies into one single long-term extension protocol that will provide patients with
continuous treatment and will continue until fingolimod is registered, commercially
available, and reimbursed in the respective countries.
efficacy, and health outcome data in all patients currently ongoing in the fingolimod
multiple sclerosis clinical development program. This study will combine all currently
ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned
studies into one single long-term extension protocol that will provide patients with
continuous treatment and will continue until fingolimod is registered, commercially
available, and reimbursed in the respective countries.
Inclusion Criteria:
- Patients who have completed selected ongoing or planned trials with FTY720.
Exclusion Criteria:
- Premature permanent discontinuation of a previous fingolimod study.
- Pregnant or nursing (lactating) women.
- Women of child-bearing potential, UNLESS they are using two birth control methods, at
least 1 of which must be hormonal contraception, tubal sterilization, partner's
vasectomy or intrauterine device.
- Chronic disease of the immune system, other than multiple sclerosis, which may require
immunosuppressive treatment.
- Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or
proliferative diabetic retinopathy and uncontrolled diabetic patients with HbA1c > 8%.
- Active systemic bacterial, viral or fungal infections, or known to have AIDS,
Hepatitis B, Hepatitis C infection or have positive HIV antibody, Hepatitis B surface
antigen or Hepatitis C antibody tests.
- Previous treatment with cladribine, cyclophosphamide or mitoxantrone.
- Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in
the past 3 months during the previous fingolimod study:
- Any of the following cardiovascular conditions that have developed during the previous
fingolimod study:
- Myocardial infarction within the past 6 months prior to entry in the extension
study or with current unstable ischemic heart disease;
- Cardiac failure (Class III, according to New York Heart Association
Classification) or any severe cardiac disease as determined by the investigator;
- Arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g.,
amiodarone, bretylium, sotalol, ibutilide, azimilide, dofetilide)
- History or presence of a third degree AV block
- Proven history of sick sinus syndrome or sino-atrial heart block
- Known history of angina pectoris due to coronary spasm or Raynaud's phenomenon
- Any of the following pulmonary conditions during the previous fingolimod study:
- Severe respiratory disease or pulmonary fibrosis diagnosed (during the previous
fingolimod study)
- Active tuberculosis
- Alcohol abuse, chronic liver disease during the previous fingolimod study.
The patient must have participated in a previous fingolimod trial to be eligible to
participate in this trial.
Other protocol-defined inclusion/exclusion criteria may apply.
We found this trial at
35
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials